Skip to main content
. 2022 Apr 10;62(4):522–529. doi: 10.1111/head.14291

TABLE 2.

Treatment effectiveness

Screening period baseline (N = 95) Week 12 (n = 95) Week 24 (n = 86)
≥50% reduction in MMD, n (%)
No 54 (56.8) 43 (50.0)
Yes 32 (33.7) 30 (34.9)
Number missing 9 (9.5) 13 (15.1)
MMD
Mean (SD) 15.7 (6.1) 10.4 (7.7) 9.7 (6.7)
Median (IQR) 14.0 (11.2, 19.0) 9.0 (4.0, 14.6) 8.52 (4.7, 12.3)
Number missing, n (%) 0 9 (9.5) 13 (15.1)
MMD changes from baseline
Mean (SD) b −4.9 (5.8) −5.7 (6.1)
Median (IQR) −4.6 (−8.0, −1.0) −5.0 (−9.3, −1.8)
Number missing, n (%) 9 (9.5) 13 (15.1)
P‐GIC, n (%)
1‐Very much improved 11 (11.6) 15 (17.4)
2‐Much improved 28 (29.5) 20 (23.3)
3‐Minimally improved 23 (24.2) 10 (11.6)
4‐No change 7 (7.4) 5 (5.8)
5‐Minimally worse 2 (2.1) 1 (1.2)
6‐Much worse 1 (1.1) 0 (0.0)
Number missing 23 (24.2) 35 (40.7)
CGI‐S a , n (%)
0‐Not assessed 1 (1.1) 5 (5.3) 3 (3.5)
1‐Normal, not at all ill 28 (29.5) 23 (24.2) 21 (24.4)
2‐Borderline mentally ill 1 (1.1) 16 (16.8) 19 (22.1)
3‐Mildly ill 15 (15.8) 22 (23.2) 18 (20.9)
4‐Moderately ill 29 (30.5) 23 (24.2) 16 (18.6)
5‐Markedly ill 12 (12.6) 3 (3.2) 2 (2.3)
6‐Severely ill 7 (7.4) 1 (1.1) 1 (1.2)
7‐Among the most extremely ill patients 2 (2.1) 1 (1.1) 0 (0.0)
Number missing 0 (0.0) 1 (1.1) 6 (7.0)
CGI‐I, n (%)
0‐Not assessed 2 (2.1) 2 (2.3)
1‐Very much improved 24 (25.3) 27 (31.4)
2‐Much improved 37 (38.9) 25 (29.1)
3‐Minimally improved 17 (17.9) 15 (17.4)
4‐No change 14 (14.7) 9 (10.5)
5‐Minimally worse 0 (0.0) 2 (2.3)
Number missing 1 (1.1) 6 (7.0)

Abbreviations: CGI‐I, Clinical Global Impressions‐Improvement; CGI‐S, Clinical Global Impressions‐Severity; IQR, interquartile range; MMD, monthly migraine days; P‐GIC, Patient Global Impression of Change; SD, standard deviation.

a

CGI‐S was used to assess the severity of psychopathology related to migraine.

b

Changes from baseline were calculated only for patients where both the data at baseline and other timepoints (12 and 24 weeks) were available.